The August issue of the American Journal of Psychiatry reports some people have a genetic predisposition to respond to the antidepressant citalopram (Celexa). The NIMH research was based on DNA collected in the clinical trial Sequenced Treatment Alternatives to Relieve Depression (STAR*D). "We're moving steadily closer to being able to personalize treatments based on patients' genetic variations." said NIMH Director Thomas R. Insel, MD.
